New therapeutic challenges in advanced bladder cancer

Seminars in Oncology

Volumn 39, Issue 5, 2012, Pages 598-607

  Bellmunt, Joaquim ^a   Petrylak, Daniel P ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CABAZITAXEL; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; LAROTAXEL; METHOTREXATE; PACLITAXEL; PAZOPANIB; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SORAFENIB; VANDETANIB; VINBLASTINE; VINFLUNINE;

ADVANCED CANCER; ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; DRUG MEGADOSE; HUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 84866980604     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.08.007     Document Type: Article

References (62)

1. P.J. Loehrer, L.H. Einhorn, P.J. Elson A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study J Clin Oncol 10 1992 1066 1073
2. R.B. Natale, A. Yagoda, R.C. Watson, W.F. Whitmore, M. Blumenreich, D.W. Braun Methotrexate: an active drug in bladder cancer Cancer 47 1981 1246 1250
3. B.J. Roth, R. Dreicer, L.H. Einhorn Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group J Clin Oncol 12 1994 2264 2270
4. R. de Wit, W.H. Kruit, G. Stoter, M. de Boer, J. Kerger, J. Verweij Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients Br J Cancer 78 1998 1342 1345
5. W.M. Stadler, T. Kuzel, B. Roth, D. Raghavan, F.A. Dorr Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer J Clin Oncol 15 1997 3394 3398
6. W.G. Harker, F.J. Meyers, F.S. Freiha Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract A Northern California Oncology Group study J Clin Oncol 3 1985 1463 1470
7. B.J. Roth, D.F. Bajorin Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world J Urol 153 1995 894 900
8. C.N. Sternberg, A. Yagoda, H.I. Scher Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium Efficacy and patterns of response and relapse Cancer 64 1989 2448 2458
9. J. Bellmunt, S. Albiol, C. Suárez, J. Albanell Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents Crit Rev Oncol Hematol 69 2009 211 222
10. NCCN clinical practice guidelines in oncology; bladder cancer Version 1.2012 http://www.nccn.org/index.asp
11. C.J. Logothetis, F.H. Dexeus, L. Finn A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors J Clin Oncol 8 1990 1050 1055
12. H. von der Maase, S.W. Hansen, J.T. Roberts Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 2000 3068 3077
13. C.N. Sternberg, P.H. de Mulder, J.H. Schornagel Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol no. 30924 J Clin Oncol 19 2001 2638 2646
14. A. Bamias, G. Aravantinos, C. Deliveliotis Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group J Clin Oncol 22 2004 220 228
15. R. Dreicer, J. Manola, B.J. Roth Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium Cancer 100 2004 1639 1645
16. C.N. Sternberg, P. de Mulder, J.H. Schornagel Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours Eur J Cancer 42 2006 50 54
17. V. Lorusso, C.F. Pollera, M. Antimi A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum Italian Co-operative Group on Bladder Cancer Eur J Cancer 34 1998 1208 1212
18. M.J. Moore, I.F. Tannock, D.S. Ernst, S. Huan, N. Murray Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer J Clin Oncol 15 1997 3441 3445
19. H. von der Maase, L. Andersen, L. Crinò, S. Weinknecht, L. Dogliotti Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial Ann Oncol 10 1999 1461 1465
20. M.J. Moore, E.W. Winquist, N. Murray Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 17 1999 2876 2881
21. D. Kaufman, D. Raghavan, M. Carducci Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer J Clin Oncol 18 2000 1921 1927
22. H. von der Maase, L. Sengelov, J.T. Roberts Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 2005 4602 4608
23. J. Bellmunt, A. Orsola, T. Wiegel Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 22 Suppl 6 2011 vi45 vi49
24. A. Bamias, A. Karadimou, S. Lampaki Prospective, randomized phase III study comparing two intensified regimens (methotrexate/vinblastine/doxorubicin hydrochloride/cisplatin [MVAC] versus gemcitabine/cisplatin) in patients with inoperable or recurrent urothelial cancer editors J Clin Oncol 29 2011 (suppl; abstr 4510)
25. J. Bellmunt, V. Guillem, L. Paz-Ares Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium Spanish Oncology Genitourinary Group J Clin Oncol 18 2000 3247 3255
26. J. Bellmunt, J. Albanell, L. Paz-Ares Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine Cancer 95 2002 751 757
27. Bellmunt J, von der Maase H, Mead G, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy; EORTC Intergroup study 30987. J Clin Oncol. In press.
28. M.D. Galsky, N.M. Hahn, J. Rosenberg A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy Lancet Oncol 12 2011 211 214
29. M. De Santis, J. Bellmunt, G. Mead Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II - results of EORTC study 30986 J Clin Oncol 27 2009 5634 5639
30. M. De Santis, J. Bellmunt, G. Mead Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin-based chemotherapy (CHT): phase III results of EORTC study 30986 editors J Clin Oncol 30 2012 191 199
31. M.E. Charlson, P. Pompei, K.L. Ales, C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
32. Pfister DJ, Thüer D, Epplen R, et al. Gemcitabine-based chemotherapy in elderly patients with advanced and metastatic urothelial cancer: the role of age and comorbidities on therapy-caused morbidity and mortality. 2010 Genitourinary Cancer Symposium, General Poster Session. Abstract 292.
33. D. Raghavan, C. Tangen, C. Moinpour, C. Gotay Paclitaxel gemcitabine (P-G) for patients (pts) with advanced urothelial cancer (UC) age > 70 years (yrs): SWOG 0028 J Clin Oncol 28 suppl 2010 abstract 4569
34. S. Culine, C. Theodore, M. De Santis A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen Br J Cancer 94 2006 1395 1401
35. D.J. Vaughn, S. Srinivas, W.M. Stadler Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study Cancer 115 2009 4110 4117
36. J. Bellmunt, C. Théodore, T. Demkov Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract J Clin Oncol 27 2009 4454 4461
37. D.F. Bajorin, P.M. Dodd, M. Mazumdar Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy J Clin Oncol 17 1999 3173 3181
38. J. Bellmunt, T.K. Choueiri, R. Fougeray Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens J Clin Oncol 28 2010 1850 1855
39. K.M. Krajewski, R. Fougeray, J. Bellmunt Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine Eur J Cancer 48 2012 1495 1502
40. P. Albers, S.I. Park, G. Niegisch Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99] Ann Oncol 22 2011 288 294
41. S.R. Wedge, D.J. Ogilvie, M. Dukes ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res 62 2002 4645 4655
42. T.K. Choueiri, R.W. Ross, S. Jacobus Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer J Clin Oncol 30 2012 507 512
43. S.S. Sridhar, C.M. Canil, S.D. Mukherjee Results of a phase II study of single-agent nab-paclitaxel in platinum-refractory second-line metastatic urothelial carcinoma (UC) editors J Clin Oncol 29 2011 (suppl 7; abstr 241)
44. R.L. Bai, K.D. Paull, C.L. Herald, L. Malspeis, G.R. Pettit, E. Hamel Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data J Biol Chem 266 1991 15882 15889
45. J.A. Smith, L. Wilson, O. Azarenko Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability Biochemistry 49 2010 1331 1337
46. S. Goel, A.C. Mita, M. Mita A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies Clin Cancer Res 15 2009 4207 4212
47. A.R. Tan, E.H. Rubin, D.C. Walton Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors Clin Cancer Res 15 2009 4213 4219
48. T.W. Synold, Dd. Tsao-Wei, D.I. Quinn et al. Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): a California Cancer Consortium trial editors J Clin Oncol 28 2010 15s (suppl; abstr 2527)
49. D.I. Quinn, A. Aparicio, D.D. Tsao-Wei Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC) - final report: a California Cancer consortium-led NCI/CTEP-sponsored trial editors J Clin Oncol 28 suppl 2010 15s (abstr 4539)
50. M.D. Galsky, S. Mironov, A. Iasonos, J. Scattergood, M.G. Boyle, D.F. Bajorin Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma Invest New Drugs 25 2007 265 270
51. L.G. Feun, N. Savaraj, P. Benedetto, S. Waldman, M. Collier, N.J. Clendennin Oral piritrexim in advanced bladder cancer: an effective drug after progression on MVAC chemotherapy? Am J Clin Oncol 17 1994 448 451
52. M. Khorsand, J. Lange, L. Feun, N.J. Clendeninn, M. Collier, G. Wilding Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder Invest New Drugs 15 1997 157 163
53. B.J. Roth, J. Manola, R. Dreicer, D. Graham, G. Wilding Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group Invest New Drugs 20 2002 425 429
54. E. Izbicka, A. Diaz, R. Streeper Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers Cancer Chemother Pharmacol 64 2009 993 999
55. H. von der Maase, L. Sengelov, J.T. Roberts Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 2005 4602 4608
56. D.P. Petrylak, H.I. Scher, V. Reuter, J.P. O'Brien, C. Cordon-Cardo P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder Ann Oncol 5 1994 835 840
57. Y. Tada, M. Wada, K. Kuroiwa MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment Clin Cancer Res 6 2000 4618 4627
58. C.R. Yang, Y.C. Ou, J.H. Kuo Intracellular glutathione content of urothelial cancer in correlation to chemotherapy response Cancer Lett 119 1997 157 162
59. J. Bellmunt, L. Paz-Ares, M. Cuello Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy Ann Oncol 18 2007 522 528
60. A.C. Hoffmann, P. Wild, C. Leicht MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy Neoplasia 12 2010 628 636
61. R.J. Cote, D. Esrig, S. Groshen, P.A. Jones, D.G. Skinner p53 and treatment of bladder cancer Nature 385 1997 123 125
62. W.M. Stadler, S.P. Lerner, S. Groshen Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status J Clin Oncol 29 2011 3443 3449